
Carla Demuro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11188841/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Review of Patient-Reported Outcome Labeling in the United States (2011–2015). Value in Health, 2017, 20, 420-429.	0.3	41
2	Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 125-134.	0.9	28
3	Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014). Journal of Clinical Oncology, 2016, 34, 1928-1934.	1.6	47
4	Development of the sporadic inclusion body myositis physical functioning assessment. Muscle and Nerve, 2016, 54, 653-657.	2.2	17
5	Overcoming Organizational Challenges of Integrating Patient-Reported Outcomes in Oncology Clinical Trials. Therapeutic Innovation and Regulatory Science, 2015, 49, 822-830.	1.6	4
6	Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems. Value in Health Regional Issues, 2015, 8, 49-55.	1.2	3
7	Promotion of Patient-Reported Outcome Label Claims Based on Nonprimary Endpoints. Therapeutic Innovation and Regulatory Science, 2014, 48, 557-563.	1.6	0
8	Potential of patient-reported outcomes as nonprimary endpoints in clinical trials. Health and Quality of Life Outcomes, 2013, 11, 83.	2.4	29
9	Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006–2010). Value in Health, 2013, 16, 1150-1155.	0.3	70
10	Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemporary Clinical Trials, 2013, 35, 62-69.	1.8	16
11	US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 441-446.	1.4	40
12	Role of Patient-Reported Outcome Measures in the Assessment of Central Nervous System Agents. Therapeutic Innovation and Regulatory Science, 2013, 47, 613-618.	1.6	5
13	A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010. Value in Health, 2012, 15, 437-442.	0.3	106
14	Reasons for Rejection of Patient-Reported Outcome Label Claims: A Compilation Based on a Review of Patient-Reported Outcome Use among New Molecular Entities and Biologic License Applications, 2006–2010. Value in Health, 2012, 15, 443-448.	0.3	44